Penicillin-binding proteins (PBPs) are involved in the synthesis and remodeling of bacterial peptidoglycan (PG). Staphylococcus aureus expresses four PBPs. Genetic studies in S. aureus have implicated PBP4 in the formation of highly cross-linked PG, but biochemical studies have not reached a consensus on its primary enzymatic activity. Using synthetic Lipid II, we show here that PBP4 preferentially acts as a transpeptidase (TP) in vitro. Moreover, it is the PBP primarily responsible for incorporating exogenous d-amino acids into cellular PG, implying that it also has TP activity in vivo. Notably, PBP4 efficiently exchanges d-amino acids not only into PG polymers but also into the PG monomers Lipid I and Lipid II. This is the first demonstration that any TP domain of a PBP can activate the PG monomer building blocks. Exploiting the promiscuous TP activity of PBP4, we developed a simple, highly sensitive assay to detect cellular pools of lipid-linked PG precursors, which are of notoriously low abundance. This method, which addresses a longstanding problem, is useful for assessing how genetic and pharmacological perturbations affect precursor levels, and may facilitate studies to elucidate antibiotic mechanism of action.
Penicillin-binding proteins (PBPs) are involved in the synthesis and remodeling of bacterial peptidoglycan (PG). Staphylococcus aureus expresses four PBPs. Genetic studies in S. aureus have implicated PBP4 in the formation of highly cross-linked PG, but biochemical studies have not reached a consensus on its primary enzymatic activity. Using synthetic Lipid II, we show here that PBP4 preferentially acts as a transpeptidase (TP) in vitro. Moreover, it is the PBP primarily responsible for incorporating exogenous d-amino acids into cellular PG, implying that it also has TP activity in vivo. Notably, PBP4 efficiently exchanges d-amino acids not only into PG polymers but also into the PG monomers Lipid I and Lipid II. This is the first demonstration that any TP domain of a PBP can activate the PG monomer building blocks. Exploiting the promiscuous TP activity of PBP4, we developed a simple, highly sensitive assay to detect cellular pools of lipid-linked PG precursors, which are of notoriously low abundance. This method, which addresses a longstanding problem, is useful for assessing how genetic and pharmacological perturbations affect precursor levels, and may facilitate studies to elucidate antibiotic mechanism of action.
Bacterial cells are surrounded
by peptidoglycan (PG), a polymer consisting of long glycan strands
that are cross-linked to form a protective mesh around the cell membrane.
PG polymers are assembled from a lipid-linked disaccharide-peptide
subunit (Lipid II) on the external surface of the bacterial membrane
by peptidoglycan glycosyltransferases (PGTs); cross-links are formed
between stem peptides attached to these glycan polymers by transpeptidases
(TPs) (Figure 1).[1] In many organisms, carboxypeptidases (CPs) remove the terminal d-Ala from stem peptides that have not been cross-linked.[2] TPs and CPs are collectively known as penicillin-binding
proteins (PBPs) and are typically distinguished because the former
contain two domains and hence are known as high-molecular-weight (HMW)
PBPs, while the latter contain only one domain and are known as low-molecular-weight
(LMW) PBPs.[2b] Because PG is essential to
protect the cell under osmotic stress, the enzymes involved in PG
synthesis are antibiotic targets, and there is great interest in understanding
their enzymatic mechanisms and cellular functions.[1,2] This
is particularly true for the TPs, which are the lethal targets of
the β-lactam antibiotics.[3]
Figure 1
Schematic depicting
carboxypeptidase (CP) and transpeptidase (TP)
activities of penicillin-binding proteins that make peptidoglycan
(a), and structures of the lipid-linked building blocks used (b).
Schematic depicting
carboxypeptidase (CP) and transpeptidase (TP)
activities of penicillin-binding proteins that make peptidoglycan
(a), and structures of the lipid-linked building blocks used (b).TPs and CPs have similar catalytic
mechanisms. In the first step,
the active site serine residue attacks the d-Ala-d-Ala bond of a stem peptide on PG to form an acyl-enzyme intermediate
with release of the terminal d-Ala (Figure 1a, black peptides). Subsequently, the covalent intermediate
is resolved by attack of a nucleophile.[2] In the case of a CP, the nucleophile is water, and a tetrapeptide
product is released.[4] In the case of a
TP, the nucleophile is the terminal amine from a stem peptide on an
adjacent PG polymer, and a cross-linked product is formed (Figure 1a).[5] In addition, TPs
can perform d-amino acid exchange with the terminal d-Ala.[5f,6] In this mechanism, added d-amino
acid reacts as the nucleophile with the acyl-enzyme intermediate.Staphylococcus aureusPBP4 is a LMW PBP of uncertain
cellular function. Genetic studies have shown that deleting PBP4 decreases
PG cross-linking, suggesting that it may act as a TP,[7] but biochemical studies using tripeptide model substrates
have equivocated on whether it functions as a TP, a CP, or a β-lactamase.[8] We overexpressed and purified a S. aureusPBP4 construct lacking the transmembrane helix (∼42 kDa)
and used bocillin-FL binding to verify that the TP domain was properly
folded (Supporting Information (SI), Figure S1).[9] To investigate the biochemical activities
of PBP4, we incubated it with Lys-Lipid II (Figure 1b, 1)[10] and SgtB,
a S. aureus monofunctional PGT that makes un-cross-linked
PG.[11]S. aureusLipid
II contains a pentaglycine-branched stem peptide (Figure 1b, 2) that is involved in cross-linking.[1b] To mimic the nucleophile in cross-linking, we
added glycine oligopeptides (Gly: Gly1, Gly2, Gly3, and Gly5).
The polymeric products were digested with the glycosylhydrolase mutanolysin.
The resulting muropeptide fragments were reduced with NaBH4 and then analyzed via LC/MS (Figure 2a).[5e,5f,6e] SgtB and PBP4 produced two products
in the absence of Gly: unmodified fragment A and the hydrolysis product B (Figure 2b-ii). When Gly was
added, S. aureusPBP4 preferentially incorporated
the exogenous nucleophile to produce Cx even though the
concentration of water is many orders of magnitude higher (Figure 2b-iii; see also SI, Figure S2a). We also observed efficient d-amino acid exchange when
we added d-Ser (Figure 2b-iv, d-Phe or d-Tyr (Figure S2b). Mutating the active site serine residue of PBP4 abolished all
TP activity (Figure S2b). The ability of
PBP4 to discriminate against water and incorporate glycine oligopeptides
and d-amino acids shows that it acts as a TP in vitro, unlike most other characterized LMW PBPs, which possess CP activity
exclusively (Figure S2c).[2,12]
Figure 2
S. aureus PBP4 has TP activity in vitro. (a) Schematic
of assay to monitor PBP4 activity. The PBP4-activated substrate adduct
can be attacked by water or X. Three possible degradation products
are yielded: A represents unreacted muropeptide, B is the hydrolysis
product, and C is a TP product with Gly2 or d-Ser
incorporated. (b) LC/MS extracted ion chromatograms (EICs) of a control
reaction without PBP4 (i), a reaction with PBP4 (ii), and reactions
containing PBP4 and Gly2 (iii) or d-Ser (iv).
(M+2H)/2 ions: A, 485.2; B, 449.6; C(Gly2), 506.7; C(d-Ser), 493.2. See Figure S2a for
other Gly traces.
S. aureusPBP4 has TP activity in vitro. (a) Schematic
of assay to monitor PBP4 activity. The PBP4-activated substrate adduct
can be attacked by water or X. Three possible degradation products
are yielded: A represents unreacted muropeptide, B is the hydrolysis
product, and C is a TP product with Gly2 or d-Ser
incorporated. (b) LC/MS extracted ion chromatograms (EICs) of a control
reaction without PBP4 (i), a reaction with PBP4 (ii), and reactions
containing PBP4 and Gly2 (iii) or d-Ser (iv).
(M+2H)/2 ions: A, 485.2; B, 449.6; C(Gly2), 506.7; C(d-Ser), 493.2. See Figure S2a for
other Gly traces.To assess S. aureus TP activity in cells,
we investigated
the ability of wildtype and PBP4 deletion (Δpbp4) strains[7e] to incorporate a previously
described fluorescent d-lysine probe (FDL; Figure 3a).[6c] Wildtype cells
were brightly labeled, with fluorescence concentrated at the cross-wall
where the bulk of PG synthesis takes place.[13] The Δpbp4 strain showed only faint labeling.
Complementation with the pbp4 gene restored efficient
labeling (Figure 3 and SI, Figure S3). These results confirm that S. aureusPBP4 acts as a TP in vivo and is primarily responsible
for catalyzing d-amino acid exchange into PG in S.
aureus cells.[14]
Figure 3
S. aureus PBP4 has TP activity in vivo. (a) Structures of
functionalized d-lysine probes (FDL
and BDL). (b) Mid-log phase S. aureus cells (wildtype
and Δpbp4) were treated with FDL (4 μM)
for 10 min. Images were adjusted to the same intensity scale for comparison.
Scale bar, 2 μm.
S. aureusPBP4 has TP activity in vivo. (a) Structures of
functionalized d-lysine probes (FDL
and BDL). (b) Mid-log phase S. aureus cells (wildtype
and Δpbp4) were treated with FDL (4 μM)
for 10 min. Images were adjusted to the same intensity scale for comparison.
Scale bar, 2 μm.For certain HMW PBPs, TP activity requires either ongoing
PG synthesis[5b,5d,6b,6e] or preformed uncross-linked PG polymer.[5a,5c] All previously studied LMW PBPs have less stringent substrate requirements:
their CP activity requires only a tripeptide mimic of a stem peptide
as a substrate.[4] Therefore, we wondered
what the substrate requirements are for S. aureusPBP4. To determine if preformed PG is a PBP4 substrate, 1 was polymerized with SgtB, which was heat-inactivated prior to adding
PBP4 and d-Tyr (Figure 4a-i). In a
parallel set of experiments to test if Lipid II could be a substrate, 1 was first incubated with PBP4 and d-Tyr and then
heat-inactivated prior to adding SgtB to polymerize the modified Lipid
II (Figure 4a-ii). LC/MS analysis of the reaction
products showed that d-Tyr was incorporated efficiently in
both sets of reactions (Figure 4b and SI, Figure S4a). Thus, PBP4 uses both nascent
PG and Lipid II monomers as substrates in vitro.
This is the first TP demonstrated to activate Lipid II. S.
aureus PBP4’s promiscuity in substrate recognition
has important ramifications for its cellular function. PBP4 has been
correlated with the formation of highly cross-linked PG,[7] and the capacity to act on both glycan strands
and Lipid II, independent of glycan polymerization, may allow PBP4
to add cross-links to partially cross-linked PG and to repair PG defects
in cells.[7d,15] This role may be particularly important
under stress conditions.
Figure 4
S. aureus PBP4 has promiscuous
TP activity. (a)
Schematic for analyzing PBP4 substrate tolerance. (b) LC/MS EICs of
PBP4 reactions with preformed PG (i) and Lipid II (ii) both show the d-Tyr-containing muropeptide product peak C. (M+2H)/2 ions were
extracted: A, 485.2; B, 449.6; C, 531.2.
S. aureusPBP4 has promiscuous
TP activity. (a)
Schematic for analyzing PBP4 substrate tolerance. (b) LC/MS EICs of
PBP4 reactions with preformed PG (i) and Lipid II (ii) both show the d-Tyr-containing muropeptide product peak C. (M+2H)/2 ions were
extracted: A, 485.2; B, 449.6; C, 531.2.We were prompted by the promiscuous TP activity of PBP4 to
examine
the scope of synthetic Lipid I and Lipid II analogues as substrates.
We found that PBP4 can act on canonical E. coliLipid
II, which contains a meso-diaminopimelic acid (m-DAP) in place of lysine in the stem peptide (Figure S4b).[5e] In
addition, a Lipid I analogue[16] could be
readily modified by PBP4 via d-amino acid exchange and then
converted to the corresponding Lipid II using MurG.[17] Using PBP4 and biotinylated d-Lys (BDL; Figure 3a), we readily obtained BDL-Lipid I and Lipid II
(Figure 5a and SI, Figure
S5), as well as other analogues with unnatural amino acids
in the terminal stem peptide position such as d-propargylglycine, d-7-azatryptophan, and d-Ala(d3) (Figures S4 and S5).
Figure 5
S. aureus PBP4 enables detection of cellular
lipid-linked
PG precursors. (a) Schematic of the chemoenzymatic route to BDL-Lipid
I and Lipid II analogues. (b) Western blot shows the change in cellular
levels of PG precursors upon 10 min of antibiotic treatments. Lipid-linked
PG precursors were extracted from 2 mL of S. aureus culture, subjected to BDL labeling, and blotted with streptavidin-HRP.
This unexpected TP
activity of PBP4 to label Lipid I and Lipid
II may aid in the development of assays to study PG biosynthetic processes.[18] One application is to detect cellular pools
of lipid-linked PG precursors in bacteria, which are notoriously low
in abundance. Currently, there are no facile methods to monitor their
levels.[19] Here, PBP4’s ability to
biotinylate these precursors enables a highly sensitive chemiluminescent
detection method (SI, Figure S6).[20]S. aureus cultures grown in
the presence of different antibiotics were extracted to obtain lipid-linked
PG precursors. Aliquots of the organic extracts were resuspended in
aqueous solution, and incubated with PBP4 and BDL. Reaction mixtures
were separated by gel electrophoresis and blotted with streptavidin-HRP
(Figure 5b and SI, Figure
S7). Biotinylated precursors were readily detected after a
brief exposure (∼2 s), implying that PBP4 can act on PG precursors
containing glycine branches, and levels of intermediates were consistent
with previous studies on accumulation of radiolabeled PG precursors.[19c,21] Moenomycin (MmA) and vancomycin (Vanco) treatments increased pool
levels of lipid-linked precursors, presumably because Lipid II is
no longer consumed by PGTs and therefore accumulates on the external
surface of the cell membrane. In contrast, fosfomycin (Fos), targocil
(Tar), and bacitracin (Bac) treatment all reduced pool levels, consistent
with their different mechanisms of inhibition.[22] Minimal changes were observed upon treatment with the non-cell
wall targeting antibiotic kanamycin (Kan) (Figure 5b and S7). This rapid method to
profile changes in levels of PG precursors should facilitate studies
on the mechanism of action of new antibiotics and may be useful for
genetic studies on the functions of cell wall biosynthetic enzymes.[23]S. aureusPBP4 enables detection of cellular
lipid-linked
PG precursors. (a) Schematic of the chemoenzymatic route to BDL-Lipid
I and Lipid II analogues. (b) Western blot shows the change in cellular
levels of PG precursors upon 10 min of antibiotic treatments. Lipid-linked
PG precursors were extracted from 2 mL of S. aureus culture, subjected to BDL labeling, and blotted with streptavidin-HRP.In conclusion, S. aureusPBP4 is an unusual enzyme
in PG assembly. Despite being a LMW PBP, it acts as a TP both in vitro and in vivo. It is highly promiscuous
and can activate both nascent PG and Lipid II monomers, suggesting
a biological role in installing additional cross-links in PG for greater
rigidity and possibly to repair damage. The promiscuity of PBP4 allows
facile preparation of functionalized Lipid I and Lipid II analogues
for in vitro studies, and also enables a simple and
highly sensitive chemiluminescent method to detect lipid-linked PG
precursors in cells. Coupled with genetics, this assay is useful for
studying functions of many PG biosynthetic enzymes and for profiling
novel antibiotics.
Authors: Lok-To Sham; Emily K Butler; Matthew D Lebar; Daniel Kahne; Thomas G Bernhardt; Natividad Ruiz Journal: Science Date: 2014-07-11 Impact factor: 47.728
Authors: Tania J Lupoli; Matthew D Lebar; Monica Markovski; Thomas Bernhardt; Daniel Kahne; Suzanne Walker Journal: J Am Chem Soc Date: 2013-12-17 Impact factor: 15.419
Authors: Jonathan G Swoboda; Timothy C Meredith; Jennifer Campbell; Stephanie Brown; Takashi Suzuki; Tobias Bollenbach; Amy J Malhowski; Roy Kishony; Michael S Gilmore; Suzanne Walker Journal: ACS Chem Biol Date: 2009-10-16 Impact factor: 5.100
Authors: Mario A Martinez Farias; Virginia A Kincaid; Venkatachalam R Annamalai; Laura L Kiessling Journal: J Am Chem Soc Date: 2014-06-10 Impact factor: 15.419
Authors: Michael A Welsh; Atsushi Taguchi; Kaitlin Schaefer; Daria Van Tyne; François Lebreton; Michael S Gilmore; Daniel Kahne; Suzanne Walker Journal: J Am Chem Soc Date: 2017-11-30 Impact factor: 15.419
Authors: Kiran V Mahasenan; Rafael Molina; Renee Bouley; María T Batuecas; Jed F Fisher; Juan A Hermoso; Mayland Chang; Shahriar Mobashery Journal: J Am Chem Soc Date: 2017-01-27 Impact factor: 15.419
Authors: Leigh M Matano; Heidi G Morris; Anthony R Hesser; Sara E S Martin; Wonsik Lee; Tristan W Owens; Emaline Laney; Hidemasa Nakaminami; David Hooper; Timothy C Meredith; Suzanne Walker Journal: J Am Chem Soc Date: 2017-07-28 Impact factor: 15.419
Authors: Frederick A Rubino; Sujeet Kumar; Natividad Ruiz; Suzanne Walker; Daniel E Kahne Journal: J Am Chem Soc Date: 2018-03-26 Impact factor: 15.419